A division of global drug giant
Glaxo, GlaxoSmithKline Biologicals based in Belgium is in talks with the
Hyderabad-based Biological E Ltd (BE) to purchase its vaccines division.
This vaccine division produces and
markets a range of pediatric and adult vaccines. The Diphtheria and Tetanus
vaccine has given the company a sizeable market share in the Indian vaccine
market. BE claims to be the first private sector company to enter the vaccines
current plant in Nasik faced some constraints in supplying vaccines and
therefore it would be interested in buying companies with modern manufacturing facilities
approved by international agencies like US FDA. The BE vaccine unit buyout will
give GSK Biologicals additional capacity in India.